V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers

Most human immunodeficiency virus (HIV) vaccine trials have lacked efficacy and empirical vaccine lead targets are scarce. Thus far, the only independent correlate of reduced risk of HIV-1 acquisition in humans is elevated levels of V2-specific antibodies identified in the modestly protective RV144...

Descripción completa

Detalles Bibliográficos
Autores principales: Duerr, Ralf, Gorny, Miroslaw K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789775/
https://www.ncbi.nlm.nih.gov/pubmed/31390725
http://dx.doi.org/10.3390/vaccines7030082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789775/
https://www.ncbi.nlm.nih.gov/pubmed/31390725
http://dx.doi.org/10.3390/vaccines7030082

Ejemplares similares